Month: August 2019

Visual Acuity Outcomes and Anti–Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World Analysis of 49 485 Eyes

Recently co-authored: Real-world outcomes (~50,000 eyes) of anti-VEGF therapy for AMD – only 1 letter gained at 1 year, meaningfully worse than clinical trials. Download: https://lnkd.in/efPCAD5 https://www.sciencedirect.com/science/article/pii/S2468653019302805?via%3Dihub Visual Acuity Outcomes and Anti–Vascular Endothelial Growth Factor Therapy Intensity in Neovascular Age-Related Macular Degeneration Patients: A Real-World […]

The 2017 U.S. FDA approval of the first gene therapy for a genetic disease launc…

The 2017 U.S. FDA approval of the first gene therapy for a genetic disease launched a promising new cycle of innovation in ophthalmic therapies…. https://www.youtube.com/watch?v=FNUUnJgWHUY&t= Watch the Advancements in Genetic and Regenerative Therapies panel at Ophthalmology Innovation Summit @ ASRS 2019. REGISTER for our next […]

Retina Today – Seeking Therapies for Stargardt Macular Dystrophy


Just published a brief review on Stargardt Macular Dystrophy, the most common inherited macular degeneration…Clinical trials are evaluating visual cycle modulation, complement inhibition, gene therapy, and subretinal transplantation of stem cell–derived RPE cells.

PDF for download: https://lnkd.in/efZ9dTp

Retina Today – Seeking Therapies for Stargardt Macular Dystrophy

Clinical research teams are working toward a treatment for Stargardt disease. How far have they come?


Return to main website.